Description: Palisade Bio is a late-stage biopharma company advancing therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. Palisade Bio’s innovative lead asset, LB1148, is a Phase 3-ready protease inhibitor with the potential to both reduce abdominal adhesions and help restore bowel function following surgery. Positive data from Phase 2 trials of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in return to bowel function and decrease in length of stay in ICU and hospital compared to placebo. Palisade Bio believes that its investigational therapies have the potential to address the myriad health conditions and complications associated with chronic disruption of the gastrointestinal epithelial barrier.
Home Page: www.palisadebio.com
PALI Technical Analysis
5800 Armada Drive
Carlsbad,
CA
92008
United States
Phone:
858 704 4900
Officers
| Name | Title |
|---|---|
| Mr. J. D. Finley | Interim CEO & CFO |
| Ms. Sharon McBrayer | Director of Operations |
| Mr. Robert C. McRae | Sr. VP of Operations & Strategic Devel. |
| Dr. Herbert B. Slade FAAAAI, M.D. | Chief Medical Officer |
| Mr. Ryker Willie | VP of Fin. & Corp. Controller |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0.2358 |
| Price-to-Book MRQ: | 0.2952 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2006-12-20 |
| Fiscal Year End: | December |
| Full Time Employees: | 13 |